Globus Medical Earnings Call Signals Profitable Momentum

Globus Medical ((GMED)) has held its Q1 earnings call. Read on for the main highlights of the call.

Globus Medical’s latest earnings call struck an optimistic tone as management highlighted robust revenue growth, sharp margin expansion, and record non‑GAAP EPS, underpinned by strong cash generation and international momentum. While integration of Nevro and shifting tech deal structures created some near‑term noise, executives stressed that durable margin gains and operational leverage are firmly on track.

Revenue Surges on Broad-Based Strength

Globus posted Q1 revenue of $759.9 million, up 27.0% as reported and 25.5% on a constant currency basis, reflecting broad-based strength across the portfolio. Management emphasized that growth was not reliant on any single product or geography, underscoring a diversified engine that is scaling effectively.

Margins Expand and EPS Hits Record Levels

Fully diluted non‑GAAP EPS climbed 64.7% year over year to $1.12, with GAAP EPS at $0.90, as margins expanded meaningfully. Adjusted gross margin improved to 69.2% and GAAP gross margin rose to 66.4% from 63.6%, driving an adjusted EBITDA margin of 32.3% and signaling profitable growth.

Base Business Delivers Healthy Organic Growth

Base business revenue reached $677.2 million, rising 13.2% as reported and 11.9% in constant currency, demonstrating solid organic momentum. Base musculoskeletal revenue of $650.3 million increased 12.9%, suggesting the legacy Globus engine continues to grow at a healthy double‑digit clip.

U.S. Spine Continues to Gain Market Share

U.S. Spine remained a standout, growing around 10% for the third consecutive quarter and marking 58 straight weeks of growth. Management attributed the performance largely to share gains across multiple implant categories, reinforcing Globus’s competitive position in its core market.

Robotics and Enabling Technologies Gain Traction

Enabling Technologies revenue rose about 21% year over year to $26.9 million, supported by increasing adoption of the ExcelsiusGPS platform. The system has now been used in nearly 130,000 robotic procedures, providing a growing installed base that fuels implant pull‑through and cross‑selling opportunities.

International and Trauma Businesses Accelerate

International Spine revenue grew 16.4% as reported and 9.8% in constant currency, adding another leg to the growth story. The trauma franchise surged 34% year over year, with neuromonitoring and trauma each exceeding 30% growth and PRECICE manufacturing now fully supplying demand.

Regulatory Wins in Patient-Specific Implants

Early in the second quarter, Globus secured two FDA 510(k) clearances for patient-specific Scripps lumbar spacers and rods, spanning seven systems. Management said these approvals make Globus the only company offering a fully integrated patient-specific lumbar implant portfolio tied to its enabling technologies.

Strong Cash Position and Shareholder Returns

The balance sheet ended Q1 with $799.3 million in cash, cash equivalents, and marketable securities, up from $629.1 million, reflecting robust cash generation. Operating cash flow reached $202.4 million, capex represented 5.2% of sales, and the company reiterated its $500 million buyback plan, with $390 million in repurchase capacity and no debt.

Nevro Integration Drives Volatility

Nevro contributed $82.7 million of revenue in Q1 but declined $17.1 million sequentially, or 17.1% versus Q4 2025, as the business underwent structural changes and sales realignment. Management cautioned that Nevro may deteriorate further before stabilizing, with a return to historical run‑rate only expected late in the back half of the year.

Nevro’s High SG&A Weighs on Profitability

Total SG&A rose to $297.8 million, or 39.2% of sales, with Nevro responsible for $46.1 million of that expense base. At 55.7% of Nevro sales, this elevated SG&A intensity highlights the near‑term drag from integration and reorganization before synergies are realized.

Shift Toward Leasing in Enabling Tech

Management noted a shift in the enabling technologies pipeline toward leases and rentals rather than outright system sales, which dampens upfront revenue recognition. While this mix change can mute near‑term top‑line growth despite a healthy pipeline, the company sees it as a more recurring, attractive long‑term model.

Cautious Stance on Revenue Outlook

Despite a strong first quarter and higher EPS guidance, Globus chose not to lift its full‑year revenue outlook, citing uncertainty around enabling tech mix and Nevro’s volatility. The decision signals that management is unwilling to bake in upside until these moving pieces become more predictable.

Competition Lengthens Robotics Sales Cycles

Executives acknowledged that intensifying competition in robotics is stretching hospital decision timelines as buyers evaluate multiple offerings. While Globus believes Excelsius maintains advantages, the broader competitive backdrop is slowing deal cadence even as overall interest in robotic solutions rises.

R&D Investments to Reaccelerate

R&D spending fell to 4.8% of sales in Q1, partly reflecting synergy capture and integration efficiencies, but management does not see this as a new normal. The company plans to ramp R&D back to 5%–6% of net sales across 2026, accepting higher near‑term investment to support its innovation pipeline.

Guidance Points to Profitable Scaling

Globus reaffirmed 2026 revenue guidance at $3.18 billion to $3.22 billion, implying 8.2% to 9.6% growth, while raising non‑GAAP EPS to $4.70–$4.80, targeting 18.1% to 20.6% expansion. Management expects adjusted gross margin around 69%–70% this year, moving toward a mid‑70s long‑term target, and plans R&D at roughly 5%–6% of sales, signaling confidence in sustained profitable scaling.

Globus Medical’s earnings call painted a picture of a company balancing short‑term integration headwinds with clear structural gains in margins, cash flow, and market share. For investors, the message was one of disciplined execution and cautious optimism, with management prioritizing sustainable profitability even as it navigates Nevro volatility and evolving robotics dynamics.